ESBL-producing <i>Escherichia coli</i> and Its Rapid Rise among Healthy People

• Kawamura Kumiko

  Department of Pathophysiological Laboratory Science, Nagoya University Graduate School of Medicine,1-1-20 Daiko Minami, Higashi-ku, Nagoya, Aichi 461-8673, Japan

• Nagano Noriyuki

  Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine,3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan

• Suzuki Masahiro

  Laboratory of Bacteriology, Aichi Prefectural Institute of Public Health,7-6 Nagare, Tsuji-machi, Kita-ku, Nagoya, Aichi 462-8576, Japan

• Wachino Jun-ichi

  Department of Bacteriology, Nagoya University Graduate School of Medicine,65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan

• Kimura Kouji

  Department of Bacteriology, Nagoya University Graduate School of Medicine,65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan

• Arakawa Yoshichika

  Department of Bacteriology, Nagoya University Graduate School of Medicine,65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan

Bibliographic Information

Other Title

• ESBL-producing Escherichia coli and its rapid rise among healthy people

Abstract

Since around the 2000s, Escherichia coli (E. coli) resistant to both oxyimino-cephalosporins and fluoroquinolones has remarkably increased worldwide in clinical settings. The kind of E. coli is also identified in patients suffering from community-onset infectious diseases such as urinary tract infections. Moreover, recoveries of multi-drug resistant E. coli from the feces of healthy people have been increasingly documented in recent years, although the actual state remains uncertain. These E. coli isolates usually produce extended-spectrum β-lactamase (ESBL), as well as acquisition of amino acid substitutions in the quinolone-resistance determining regions (QRDRs) of GyrA and/or ParC, together with plasmid-mediated quinolone resistance determinants such as Qnr, AAC(6’)-Ib-cr, and QepA. The actual state of ESBL-producing E. coli in hospitalized patients has been carefully investigated in many countries, while that in healthy people still remains uncertain, although high fecal carriage rates of ESBL producers in healthy people have been reported especially in Asian and South American countries. The issues regarding the ESBL producers have become very complicated and chaotic due to rapid increase of both ESBL variants and plasmids mediating ESBL genes, together with the emergence of various “epidemic strains” or “international clones” of E. coli and Klebsiella pneumoniae harboring transferable-plasmids carrying multiple antimicrobial resistance genes. Thus, the current state of ESBL producers outside hospital settings was overviewed together with the relation among those recovered from livestock, foods, pets, environments and wildlife from the viewpoint of molecular epidemiology. This mini review may contribute to better understanding about ESBL producers among people who are not familiar with the antimicrobial resistance (AMR) threatening rising globally.

Journal

• Food Safety

  Food Safety 5 (4), 122-150, 2017

  Food Safety Commission, Cabinet Office, Government of Japan

Keywords

• <i>Escherichia coli</i>
• extended-spectrum β-lactamase (ESBL)
• food
• healthy people
• livestock

Details

• CRID: 1390282680487767296
• NII Article ID: 130006292482
• DOI: 10.14252/foodsafetyfscj.2017011
• ISSN: 21878404
• Web Site: https://www.jstage.jst.go.jp/article/foodsafetyfscj/5/4/5_2017011/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2019100053
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed